RxDoctor Payments Data

Julia Norton, PA

Physician Assistant · Meridian, IDNPI 1891279154

Payments from drug & device makers

$2,441in general payments, 2019–2025

Across 53 payments — averaging $46.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$851
  • Actelion Pharmaceuticals US, Inc.$283
  • AstraZeneca$256
  • E.r. Squibb & Sons, L.L.C.$192
  • Abiomed$146
  • Alnylam Pharmaceuticals Inc.$129
  • plus $583 from 16 others

What the payments were for

  • Travel & lodging$35415%
  • Food & beverage$2,07885%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,441 in reported general payments places this provider in the 85th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$15,166
Medicare patients
98
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan213$146,427
EliquisApixaban91$78,754
FarxigaDapagliflozin Propanediol95$64,626
JardianceEmpagliflozin70$54,108
BrilintaTicagrelor47$21,282
Repatha SureclickEvolocumab11$7,081
Bumetanide52$3,250
Torsemide75$1,620
Metoprolol Succinate141$1,453
Spironolactone223$1,220
Eplerenone23$1,218
ClopidogrelClopidogrel Bisulfate69$725
Atorvastatin Calcium92$669
Potassium Chloride40$387
Losartan Potassium61$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$23$146,427213 claims
AstraZenecaFarxiga, Brilinta$256$85,907142 claims
PfizerEliquis$25$78,75491 claims
Boehringer IngelheimJardiance$36$54,10870 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →